IPP Bureau
Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial
By IPP Bureau - May 19, 2026
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
FDA expands Enhertu use in early HER2-positive breast cancer
By IPP Bureau - May 19, 2026
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets
By IPP Bureau - May 19, 2026
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle
By IPP Bureau - May 19, 2026
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
ParexelAI launched to accelerate clinical development and improve trial efficiency
By IPP Bureau - May 19, 2026
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
Lupin debuts in Dow Jones best-in-class indices for ESG performance
By IPP Bureau - May 19, 2026
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer
By IPP Bureau - May 19, 2026
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Medix Biochemica unleashes $5 million expansion to secure future of IVD supply chain
By IPP Bureau - May 19, 2026
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Teva study exposes major diagnosis gap in Tardive Dyskinesia
By IPP Bureau - May 19, 2026
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
By IPP Bureau - May 19, 2026
Baxfendy works in a fundamentally different way from current therapies
Zeus Hygia launches Metaberine in Europe and US markets
By IPP Bureau - May 19, 2026
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Lupin launches Atharv ability neuro-rehabilitation centre in Delhi
By IPP Bureau - May 18, 2026
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
By IPP Bureau - May 18, 2026
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
